[Carboplatin-Vepeside in the treatment of non-small cell bronchial cancers. A phase II study].
Carboplatin, a derivative of cisplatin, has, when administered alone, a remission rate of almost 20 per cent. Forty-six patients were treated with the combination carboplatin/vepesid. Twenty-seven per cent of the patients experienced partial remission; in 41%, no change in the size of the tumour was observed. Neither alone nor in combination does carboplatin appear to show any nephrotoxicity or otoxicity, and its neurotoxic effect is only slight.